Opaleye Management’s Celldex Therapeutics CLDX Stock Holding History

Opaleye Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-90,000	Closed	-$2.43M	–	44
2022 Q2	$2.43M	Sell	90,000 -105,500	-54%	-$3.06M	1.09%	24
2022 Q1	$6.66M	Sell	195,500 -648,500	-77%	-$20.7M	2.07%	17
2021 Q4	$32.6M	Sell	844,000 -141,000	-14%	-$6.14M	6.92%	4
2021 Q3	$53M	Hold	985,000	–	–	9.91%	2
2021 Q2	$32.9M	Hold	985,000	–	–	5.47%	3
2021 Q1	$20.3M	Sell	985,000 -7,000	-0.7%	-$161K	2.98%	10
2020 Q4	$17.4M	Hold	992,000	–	–	2.27%	15
2020 Q3	$14.7M	Sell	992,000 -79,000	-7%	-$925K	2.88%	12
2020 Q2	$13.9M	Buy	+1,071,000	New	+$4.75M	2.81%	13

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Opaleye Management's CLDX Position: Q3 2022 in Review

Opaleye Management sold out of Celldex Therapeutics (CLDX) in Q3 2022, closing a stake of 90,000 shares — an estimated $2.43M sold.

Opaleye Management first reported a position in CLDX in Q2 2020 and held it in 9 quarters. The position peaked at $53M in Q3 2021. 158 funds tracked by Wall St. Rank hold CLDX as of Q3 2022.

Opaleye Management reported no remaining Celldex Therapeutics position as of Q3 2022 after selling out during the quarter.
Opaleye Management sold 90,000 Celldex Therapeutics shares in Q3 2022, an estimated $2.43M.
Opaleye Management first reported a position in Celldex Therapeutics in Q2 2020 and held it in 9 quarters.
Opaleye Management's Celldex Therapeutics position peaked at $53M in Q3 2021.
158 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2022.

Based on Opaleye Management's 13F filing for Q3 2022, filed 14 Nov 2022.